Lung Cancer | Clinical

Frontline Durvalumab Plus Tremelimumab and Chemotherapy Improves OS in NSCLC

May 07, 2021

The combination of durvalumab, tremelimumab, and chemotherapy showed statistically significant and clinically meaningful overall survival benefit compared to chemotherapy alone for the first-line treatment of patients with metastatic non-small cell lung cancer.

Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC

May 01, 2021

The combination of oleclumab and osimertinib was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer with an EGFR mutation after progression on an EGFR tyrosine kinase inhibitor.